Literature DB >> 34206947

How to Obtain a High Quality ctDNA in Lymphoma Patients: Preanalytical Tips and Tricks.

Estelle Bourbon1, Vincent Alcazer1, Estelle Cheli1, Sarah Huet1,2, Pierre Sujobert1,2.   

Abstract

The analysis of circulating tumor DNA (ctDNA) released by tumor cells holds great promise for patients with lymphoma, to refine the diagnostic procedure, clarify the prognosis, monitor the response to treatment, and detect relapses earlier. One of the main challenges of the coming years is to adapt techniques from highly specialized translational teams to routine laboratories as this requires a careful technical and clinical validation, and we have to achieve this as fast as possible to transform a promising biomarker into a routine analysis to have a direct consequence on patient care. Whatever the analytical technology used, the prerequisite is to obtain high yields of ctDNA of optimal quality. In this review, we propose a step-by-step description of the preanalytical process to obtain high-quality ctDNA, emphasizing the technical choices that need to be made and the experimental data that can support these choices.

Entities:  

Keywords:  ctDNA; lymphoma; preanalytical

Year:  2021        PMID: 34206947     DOI: 10.3390/ph14070617

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  42 in total

1.  About the possible origin and mechanism of circulating DNA apoptosis and active DNA release.

Authors:  M Stroun; J Lyautey; C Lederrey; A Olson-Sand; P Anker
Journal:  Clin Chim Acta       Date:  2001-11       Impact factor: 3.786

2.  Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients.

Authors:  Hao Zhang; Bin He; Jun Cui; Mingzhang Zhao; Zengwang Zhang
Journal:  Cancer Biomark       Date:  2018       Impact factor: 4.388

3.  Prognostication with circulating tumor DNA: is it ready for prime time?

Authors:  David M Kurtz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

4.  Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients.

Authors:  Kinga Tóth; Árpád V Patai; Alexandra Kalmár; Barbara Kinga Barták; Zsófia Brigitta Nagy; Orsolya Galamb; Barnabás Wichmann; Zsolt Tulassay; Béla Molnár
Journal:  Pathol Oncol Res       Date:  2016-12-30       Impact factor: 3.201

Review 5.  Circulating nucleic acids (CNAs) and cancer--a survey.

Authors:  M Fleischhacker; B Schmidt
Journal:  Biochim Biophys Acta       Date:  2006-10-07

6.  Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies.

Authors:  Luis J Herrera; Siva Raja; William E Gooding; Talal El-Hefnawy; Lori Kelly; James D Luketich; Tony E Godfrey
Journal:  Clin Chem       Date:  2004-11-11       Impact factor: 8.327

Review 7.  The translational potential of circulating tumour DNA in oncology.

Authors:  K M Patel; D W Y Tsui
Journal:  Clin Biochem       Date:  2015-04-15       Impact factor: 3.281

8.  Workshop report on the extraction of foetal DNA from maternal plasma.

Authors:  Tobias J Legler; Zhong Liu; Ariadni Mavrou; Kirstin Finning; Ilona Hromadnikova; Silvia Galbiati; Cathy Meaney; Maj A Hultén; Francesco Crea; Martin L Olsson; Deborah G Maddocks; Dorothy Huang; Sylvia Armstrong Fisher; Markus Sprenger-Haussels; Aicha Ait Soussan; C Ellen van der Schoot
Journal:  Prenat Diagn       Date:  2007-09       Impact factor: 3.050

Review 9.  The emerging role of cell-free DNA as a molecular marker for cancer management.

Authors:  Abel Jacobus Bronkhorst; Vida Ungerer; Stefan Holdenrieder
Journal:  Biomol Detect Quantif       Date:  2019-03-18

10.  Day-to-day and within-day biological variation of cell-free DNA.

Authors:  Anne Tranberg Madsen; Johanne Andersen Hojbjerg; Boe Sandahl Sorensen; Anne Winther-Larsen
Journal:  EBioMedicine       Date:  2019-10-21       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.